Abstracts tagged "T cells and rituximab"

Abstract Number: 2882 • 2013 ACR/ARHP Annual Meeting
B-Cell Depletion Modulates T-Helper Cell Balance In Patients With Primary Sjögren’s Syndrome
WH Abdulahad¹, FGM Kroese², Gwenny Verstappen³, MG Huitema¹, PM Meiners⁴, A Vissink⁵ and H Bootsma¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen and University Medical Center Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: B-cell depletion therapy with a chimeric anti-human CD20 antibody (rituximab; RTX) is an effective treatment modality for patients with primary Sjögren’s syndrome (pSS). However,…
Abstract Number: 1752 • 2012 ACR/ARHP Annual Meeting
Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing
Hamid Mattoo¹, Arezou Khosroshahi², Vinay Mahajan³, Mollie Carruthers², John Stone³ and Shiv Pillai⁴, ¹Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Boston, MA, ³Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Oncology, Massachusetts General Hospital, Boston, MA
Depletion of CD4-effector memory T cells and clonally expanded IgG4 memory B cells may explain the therapeutic efficacy of rituximab in IgG4-related disease: Studies using…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].